# NCT02684006 (NCT02684006)

> A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02684006
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Pfizer
- Conditions: Renal Cell Cancer
- Interventions: Avelumab (MSB0010718C); Axitinib (AG-013736); Sunitinib
- Enrollment: 886
- Primary outcome: Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) in Programmed Death-Ligand 1 (PD-L1) Positive Participants
- Primary outcome: Overall Survival (OS) in PD-L1 Positive Participants

## Commentary we found

- X threads: 46
- YouTube: 16
- Podcasts: 14
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct02684006

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02684006", "email": "<work email>"}; the inbox owner confirms by the emailed link.